Corcept Therapeutics Incorporated
$ 43.90
0.50%
15 Apr - close price
- Market Cap 4,646,417,000 USD
- Current Price $ 43.90
- High / Low $ 44.42 / 43.27
- Stock P/E 53.27
- Book Value 6.11
- EPS 0.82
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.15 %
- 52 Week High 91.00
- 52 Week Low 28.66
About
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Analyst Target Price
$67.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-04 | 2025-07-28 | 2025-04-29 | 2025-02-13 | 2024-10-30 | 2024-07-29 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | 0.2 | 0.16 | 0.29 | 0.1693 | 0.26 | 0.41 | 0.32 | 0.25 | 0.28 | 0.28 | 0.25 | 0.14 |
| Estimated EPS | 0.254 | 0.13 | 0.1864 | 0.1425 | 0.4233 | 0.28 | 0.23 | 0.22 | 0.26 | 0.22 | 0.15 | 0.19 |
| Surprise | -0.054 | 0.03 | 0.1036 | 0.0268 | -0.1633 | 0.13 | 0.09 | 0.03 | 0.02 | 0.06 | 0.1 | -0.05 |
| Surprise Percentage | -21.2598% | 23.0769% | 55.5794% | 18.807% | -38.5778% | 46.4286% | 39.1304% | 13.6364% | 7.6923% | 27.2727% | 66.6667% | -26.3158% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CORT
2026-04-15 21:10:03
The Rosen Law Firm is encouraging purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, to join a class action lawsuit. The deadline to serve as lead plaintiff is April 21, 2026. The lawsuit alleges that Corcept misrepresented the clinical trial support for its relacorilant drug, leading to investor damages.
2026-04-15 19:10:03
Hagens Berman has issued an investor notice for Corcept Therapeutics (CORT), urging investors with significant losses to join a class action lawsuit by the April 21, 2026, lead plaintiff deadline. The lawsuit alleges that Corcept concealed FDA warnings about its drug relacorilant's data deficiency, leading to a 50% stock price drop after the FDA issued a Complete Response Letter. Investors who bought CORT stock between October 31, 2024, and December 30, 2025, are encouraged to submit their losses.
2026-04-15 17:10:03
Glancy Prongay Wolke & Rotter LLP is reminding investors of Corcept Therapeutics Incorporated (CORT) about an April 21, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges securities fraud, stemming from the FDA's decision to decline approval for Corcept's drug relacorilant due to concerns about its effectiveness, leading to a significant drop in the company's stock price. Investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, and suffered losses are encouraged to contact the firm.
2026-04-15 01:40:00
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Corcept Therapeutics Incorporated (CORT). Investors who suffered losses between October 31, 2024, and December 30, 2025, have until April 21, 2026, to apply to be lead plaintiffs. The lawsuit alleges that Corcept failed to disclose FDA concerns regarding its relacorilant drug program, leading to "materially misleading and/or lacked a reasonable basis" statements about the company's prospects.
2026-04-14 16:40:00
Hagens Berman has issued a 1-week deadline alert for investors of Corcept Therapeutics (CORT), notifying them of the April 21, 2026, lead plaintiff deadline in a securities fraud class action lawsuit. The lawsuit alleges that Corcept concealed FDA warnings about its drug candidate relacorilant, leading to an "insufficient" evidentiary record and a subsequent 50% stock price drop. Investors who suffered significant losses between October 31, 2024, and December 30, 2025, are urged to submit their losses and consider legal action.
2026-04-14 13:00:00
The Gross Law Firm has issued a shareholder alert for Corcept Therapeutics Incorporated (NASDAQ: CORT) regarding a securities class action lawsuit. Investors who purchased CORT shares between October 31, 2024, and December 30, 2025, are encouraged to join, as the company allegedly made false and misleading statements concerning FDA concerns about its relacorilant NDA and the GRACE study design. The deadline to register as a lead plaintiff is April 21, 2026.
